TY - JOUR
T1 - Adjuvant chemotherapy of pT1a and pT1b breast carcinoma
T2 - Results from the NEMESI study
AU - Gori, Stefania
AU - Clavarezza, Matteo
AU - Siena, Salvatore
AU - Foglietta, Jennifer
AU - Tarenzi, Emiliana
AU - Giordano, Monica
AU - Molino, Annamaria
AU - Graiff, Claudio
AU - Fusco, Vittorio
AU - Alabiso, Oscar
AU - Baldini, Editta
AU - Gamucci, Teresa
AU - Altavilla, Giuseppe
AU - Dondi, Davide
AU - Venturini, Marco
N1 - Funding Information:
The NEMESI study was funded by Sanofi-Aventis. The sponsor did not interfere in any way in the interpretation of data or in the content of the manuscript.
PY - 2012/4/30
Y1 - 2012/4/30
N2 - Background: The prognosis of pT1a-pT1b breast cancer (BC) used to be considered very good, with a 10-y RFS of 90%. However, some retrospective studies reported a 10-y RFS of 81%-86% and suggested benefit from adjuvant systemic therapy.Methods: To evaluate the variables that determined the choice of adjuvant chemotherapy and the type of chemotherapy delivered in pT1a-pT1b BC, we analysed the small tumours enrolled in the NEMESI study.Results: Out of 1,894 patients with pathological stage I-II BC enrolled in NEMESI, 402 (21.2%) were pT1a-pT1b. Adjuvant chemotherapy was delivered in 127/402 (31.59%). Younger age, grading G3, high proliferative index, ER-negative and HER2-positive status were significantly associated with the decision to administer adjuvant chemotherapy. An anthracycline without taxane regimen was administered in 59.1% of patients, anthracycline with taxane in 24.4%, a CMF-like regimen in 14.2% and taxane in 2.4%. Adjuvant chemotherapy was administered in 88.4% triple-negative and 73.46% HER2-positive pT1a-pT1b BC. Adjuvant trastuzumab was delivered in 30/49 HER2-positive BC (61.2%).Conclusions: Adjuvant chemotherapy was delivered in 31.59% T1a-pT1b BC treated at 63 Italian oncological centres from January 2008 to June 2008. The choice to deliver chemotherapy was based on biological prognostic factors. Anthracycline-based chemotherapy was administered in 83.5% patients.
AB - Background: The prognosis of pT1a-pT1b breast cancer (BC) used to be considered very good, with a 10-y RFS of 90%. However, some retrospective studies reported a 10-y RFS of 81%-86% and suggested benefit from adjuvant systemic therapy.Methods: To evaluate the variables that determined the choice of adjuvant chemotherapy and the type of chemotherapy delivered in pT1a-pT1b BC, we analysed the small tumours enrolled in the NEMESI study.Results: Out of 1,894 patients with pathological stage I-II BC enrolled in NEMESI, 402 (21.2%) were pT1a-pT1b. Adjuvant chemotherapy was delivered in 127/402 (31.59%). Younger age, grading G3, high proliferative index, ER-negative and HER2-positive status were significantly associated with the decision to administer adjuvant chemotherapy. An anthracycline without taxane regimen was administered in 59.1% of patients, anthracycline with taxane in 24.4%, a CMF-like regimen in 14.2% and taxane in 2.4%. Adjuvant chemotherapy was administered in 88.4% triple-negative and 73.46% HER2-positive pT1a-pT1b BC. Adjuvant trastuzumab was delivered in 30/49 HER2-positive BC (61.2%).Conclusions: Adjuvant chemotherapy was delivered in 31.59% T1a-pT1b BC treated at 63 Italian oncological centres from January 2008 to June 2008. The choice to deliver chemotherapy was based on biological prognostic factors. Anthracycline-based chemotherapy was administered in 83.5% patients.
KW - Adjuvant chemotherapy
KW - Adjuvant hormonal therapy
KW - PT1a and pT1b breast cancer
UR - https://www.scopus.com/pages/publications/84865302905
U2 - 10.1186/1471-2407-12-158
DO - 10.1186/1471-2407-12-158
M3 - Article
SN - 1471-2407
VL - 12
JO - BMC Cancer
JF - BMC Cancer
M1 - 158
ER -
